Whereas, in the second and third cluster, the genes IGFBP2 (targeted by vasodilators) and ADRB2 (targeted by β-blockers), respectively, have been recently linked with increased risk of HTN and have been recently proposed as potential diagnostic biomarkers for HTN. Here, ADRB2 is linked to hypertensive disorder.